Radioimmunotherapy Market Size, Share, and Growth Forecast 2026 - 2033

The global radioimmunotherapy market size is expected to be valued at US$2.1 billion in 2026 and projected to reach US$3.8 billion by 2033, growing at a CAGR of 8.8% between 2026 and 2033, driven by the increasing adoption of targeted cancer therapies that deliver radiation directly to tumor cells while reducing damage to surrounding healthy tissues.

The rising incidence of lymphoma, neuroendocrine tumors, and prostate cancer, along with advancements in radiopharmaceuticals and precision medicine, is boosting the adoption of radioimmunotherapy. Furthermore, growing investments in radioisotope production, expansion of nuclear medicine infrastructure, and a robust pipeline of antibody-based radiotherapies are supporting market expansion. Continued regulatory approvals of innovative radioligand therapies, strategic partnerships among biotechnology companies and healthcare providers, and ongoing clinical research are expected to further drive the market's long-term growth.

Drivers - Blockbuster Commercial Success of Lutetium-177 Therapies Validates Category

Commercial performance of approved lutetium-177 radioligand therapies has fundamentally reshaped investor and clinical confidence in radioimmunotherapy as a mainstream oncology treatment modality. Novartis AG's Pluvicto, approved by the U.S. Food and Drug Administration for PSMA-positive metastatic prostate cancer, generated substantial commercial sales within its first years on the market, demonstrating strong physician and patient adoption. This commercial validation builds directly on the earlier success of Lutathera, a lutetium-177 therapy for neuroendocrine tumors that established regulatory and manufacturing precedent years earlier.

The National Cancer Institute continues funding research into expanding radioligand therapy applications across additional solid tumor types. This proven commercial pathway is encouraging pharmaceutical companies and biotechnology investors to substantially increase capital allocation toward radioimmunotherapy pipeline development, reinforcing sustained structural demand growth across the broader radiopharmaceutical industry worldwide.

Expanding Clinical Pipeline Targeting Novel Tumor Antigens

Clinical pipeline expansion beyond established antigen targets continues broadening the addressable patient population for radioimmunotherapy products. Companies including Fusion Pharmaceuticals and POINT Biopharma have advanced multiple radioligand candidates targeting antigens beyond the historically dominant CD20 and PSMA categories into clinical trials.

The U.S. Food and Drug Administration has granted fast-track and breakthrough therapy designations to several radioimmunotherapy candidates, reflecting regulatory recognition of strong early efficacy signals across difficult-to-treat cancer types. This expanding pipeline diversity reduces the category's historical reliance on a small number of approved products, broadening commercial opportunity across lymphoma, neuroendocrine, breast, and prostate cancer indications simultaneously. As more antigen-targeted candidates progress through late-stage trials, this pipeline depth continues reinforcing long-term structural demand growth for radioimmunotherapy manufacturing and distribution infrastructure worldwide.

Restraints - Complex Manufacturing and Radioisotope Supply Constraints

Radioimmunotherapy products depend on specialized radioisotope production infrastructure with inherently limited global supply capacity. The International Atomic Energy Agency has documented recurring supply chain vulnerabilities affecting medical radioisotope availability, including reactor and cyclotron capacity constraints. Lutetium-177 and other therapeutic isotopes require specialized nuclear reactor access, concentrated among a limited number of global suppliers including ITM Isotope Technologies Munich SE. This supply concentration creates production bottlenecks that can delay patient treatment access and limit manufacturers' ability to scale output quickly in response to rising clinical demand, particularly during periods of reactor maintenance or unexpected supply disruption. Smaller biotechnology developers without diversified isotope sourcing agreements face particular exposure to these recurring supply constraints.

High Treatment Costs Limit Broad Patient Access

Radioimmunotherapy treatment courses carry substantial per-patient costs compared with conventional oncology therapies, reflecting specialized manufacturing, handling, and administration requirements. Health insurance reimbursement frameworks in several countries continue evolving to accommodate these novel high-cost radiopharmaceutical therapies, creating temporary access friction for eligible patients. Specialized radiation safety infrastructure required at treatment facilities further limits the number of centers capable of administering these therapies. This cost and infrastructure barrier continues constraining broader patient access, particularly across smaller hospitals and facilities lacking dedicated nuclear medicine departments capable of handling radioactive therapeutic agents safely. Patients in rural or underserved regions often face considerable travel burden to reach one of the limited certified treatment centers nationwide.

Opportunities - Expanding Antibody-Radionuclide Conjugate Pipeline Innovation

Monoclonal antibody-based radioimmunotherapy represents the fastest-growing product category through 2033, propelled by renewed pharmaceutical industry investment in antibody-radionuclide conjugate technology combining targeted antibodies with alpha or beta-emitting isotopes. Companies including Actinium Pharmaceuticals and Y-mAbs Therapeutics continue advancing antibody-based radioconjugate candidates through clinical trials targeting hematologic malignancies and solid tumors. This renewed antibody-based innovation builds on decades of monoclonal antibody manufacturing expertise already established across the broader biopharmaceutical industry, lowering technical barriers relative to entirely novel drug modalities.

Companies capable of combining proven antibody engineering capabilities with radioisotope conjugation expertise stand to capture meaningful competitive advantage as this pipeline matures, particularly as alpha-emitting isotopes demonstrate strong early efficacy signals across multiple difficult-to-treat cancer indications entering late-stage clinical development over the coming years.

Geographic Expansion of Radiopharmaceutical Manufacturing Capacity

Asia Pacific represents a substantial expansion opportunity as regional governments and manufacturers invest in radiopharmaceutical production infrastructure to reduce dependence on imported isotopes. Companies including Telix Pharmaceuticals have pursued regional manufacturing and distribution partnerships to establish local supply chains across key Asia Pacific markets.

Growing cancer incidence across the region, combined with expanding nuclear medicine infrastructure investment by national governments, is creating substantial new demand for locally accessible radioimmunotherapy products. Companies that establish early regional manufacturing partnerships and secure local regulatory approval pathways stand to capture significant first-mover advantage as Asia Pacific healthcare systems continue expanding access to advanced oncology treatment modalities over the coming forecast period.

Product Type Insights

Radioisotope-based radioimmunotherapy is expected to lead product type segmentation, commanding the largest share of the global radioimmunotherapy market in 2026. This leadership reflects the commercial dominance of lutetium-177-based products, including Novartis AG's Pluvicto and Lutathera, both of which target specific cell surface receptors using radiolabeled small molecules and peptides rather than full monoclonal antibodies. These radioisotope-based products benefit from simpler manufacturing processesand favorable tumor penetration characteristics compared with larger antibody-based constructs.

Meanwhile, monoclonal antibody-based radioimmunotherapy is the fastest-growing product type through 2033, propelled by renewed pharmaceutical investment in antibody-radionuclide conjugate technology targeting hematologic malignancies and solid tumors across an expanding late-stage clinical pipeline. Smaller molecular size also allows radioisotope-based agents to clear the bloodstream faster, reducing off-target radiation exposure for patients.

Radioisotope insights

Lutetium-177 is expected to lead radioisotope segmentation, commanding an estimated 42% share of the global radioimmunotherapy market in 2026. This leadership stems directly from the commercial success of Novartis AG's Pluvicto and Lutathera, both approved by the U.S. Food and Drug Administration and now generating substantial global sales across prostate cancer and neuroendocrine tumor indications. Lutetium-177's favorable beta-emission profile and manageable half-life make it well-suited for outpatient administration compared with alternative isotopes.

Meanwhile, Yttrium-90 is the fastest-growing radioisotope through 2033, supported by expanding clinical research into its application across liver-directed radioembolization and antibody-conjugate therapy platforms among emerging biotechnology developers. Its higher-energy beta emission also continues attracting research interest for treating larger or more radioresistant tumor masses.

Target Antigen Insights

PSMA is expected to lead target antigen segmentation, reflecting the commercial dominance of prostate-specific membrane antigen-targeted therapies following Pluvicto's regulatory approval and strong market uptake. Prostate cancer's substantial patient population, combined with PSMA's high expression specificity on prostate cancer cells, has made this antigen the most commercially validated target within the radioimmunotherapy category. The National Cancer Institute continues supporting expanded clinical research into PSMA-targeted combination therapy approaches.

Meanwhile, HER2 is likely to be the fastest-growing target antigen through 2033, propelled by expanding radioconjugate research targeting HER2-positive breast cancer patients who have exhausted conventional antibody-drug conjugate treatment options. Continued biomarker screening advances are also helping clinicians identify eligible patients more precisely across both antigen categories.

End-user Insights

Cancer treatment centers are expected to lead end-user segmentation, reflecting these specialized facilities' established radiation safety infrastructure and dosimetry expertise required for radioimmunotherapy administration. Specialized oncology centers maintain dedicated nuclear medicine departments capable of handling radioactive therapeutic agents safely, a capability many general hospitals lack. Companies including Curium Pharma and Lantheus Holdings maintain strong distribution relationships with these specialized treatment networks.

Meanwhile, Hospitals represent the fastest-growing end-user segment, as broader hospital nuclear medicine departments increasingly invest in radiation safety infrastructure to expand patient access to radioligand therapy beyond specialized cancer treatment centers alone. Research institutes continue playing a supporting role by advancing early-stage antigen discovery work that feeds new candidates into the clinical pipeline.

North America Radioimmunotherapy Market Trends

North America leads the global radioimmunotherapy market, supported by well-established U.S. Food and Drug Administration (FDA) regulatory pathways, strong reimbursement frameworks, and a dense network of specialized cancer treatment centers. The region also benefits from advanced nuclear medicine infrastructure, high adoption of precision oncology, and continued investment in radiopharmaceutical manufacturing. Commercial success of approved lutetium-177-based therapies and a robust clinical trial pipeline continue reinforcing North America's leadership across both academic medical centers and community oncology settings.

U.S. Radioimmunotherapy Market Trends

The U.S. is expected to account for an estimated 82% of the global radioimmunotherapy market. The country benefits from the strong presence of leading developers, including Novartis AG, Lantheus Holdings, and several emerging radiopharmaceutical innovators. Expanding production capacity for medical isotopes, increasing clinical adoption of targeted radioligand therapies, and growing investment in nuclear medicine facilities continue supporting sustained double-digit market growth across the country.

Europe Radioimmunotherapy Market Trends

Europe represents a mature and innovation-driven radioimmunotherapy market, shaped by coordinated European Medicines Agency (EMA) regulatory pathways, extensive academic research, and a well-developed nuclear medicine ecosystem. Strong collaboration between research institutions, healthcare providers, and radiopharmaceutical manufacturers is accelerating clinical development and commercialization. Continued investments in isotope production facilities and radiopharmaceutical manufacturing across Germany, France, and neighboring countries are reinforcing stable regional market expansion.

Germany Radioimmunotherapy Market Trends

Germany stands among Europe's largest radioimmunotherapy markets, anchored by domestic radioisotope manufacturer ITM Isotope Technologies Munich SE and a strong network of university hospitals specializing in nuclear medicine. Government support for biotechnology innovation, expanding radiopharmaceutical production capacity, and active participation in clinical research continue strengthening Germany's position as a leading European hub for radioimmunotherapy development and commercialization.

U.K. Radioimmunotherapy Market Trends

The U.K. maintains a prominent position within Europe's radioimmunotherapy landscape, supported by National Health Service (NHS) oncology infrastructure, world-class academic research institutions, and increasing investment in precision cancer care. Continued NHS funding for specialized cancer centers, along with expanding access to radioligand therapies through clinical programs, is supporting broader nationwide adoption and long-term market growth.

France Radioimmunotherapy Market Trends

France continues to strengthen its position in the radioimmunotherapy market through sustained investment in nuclear medicine infrastructure and oncology research. Support from the National Cancer Institute, increasing public-private partnerships, and growing radiopharmaceutical manufacturing capabilities are accelerating clinical innovation. These factors continue to drive wider adoption of targeted radionuclide therapies across major oncology treatment centers throughout the country.

Asia Pacific Radioimmunotherapy Market Trends

Asia Pacific is projected to register the fastest regional growth through 2033, driven by rising cancer incidence, expanding healthcare expenditure, and increasing investment in nuclear medicine infrastructure. Growing domestic radiopharmaceutical manufacturing capabilities, supportive government initiatives, and broader access to advanced oncology treatments are accelerating market expansion. China, Japan, South Korea, and India are expected to remain the primary contributors to regional growth over the forecast period.

India Radioimmunotherapy Market Trends

India is emerging as a high-potential radioimmunotherapy market, supported by expanding oncology care infrastructure, increasing government investment in nuclear medicine, and rising awareness of targeted cancer therapies. Growing collaboration between hospitals, research institutes, and radiopharmaceutical manufacturers is improving treatment accessibility. In addition, increasing cancer incidence, expanding PET/CT and nuclear medicine facilities, and ongoing investment in domestic radioisotope production are expected to drive robust market growth during the forecast period.

The global radioimmunotherapy market remains moderately concentrated, dominated by Novartis AG following Pluvicto and Lutathera's strong commercial performance. Competitive differentiation centers on radioisotope manufacturing capacity, clinical pipeline breadth, and antigen-targeting innovation.

Companies including Telix Pharmaceuticals and Fusion Pharmaceuticals continue advancing differentiated radioligand candidates targeting novel antigens and alpha-emitting isotope platforms. Strategic partnerships between radiopharmaceutical developers and isotope suppliers, including ITM Isotope Technologies Munich SE, represent a growing business model trend addressing supply chain security across the expanding competitive landscape.

Key Industry Developments:

• In May 2026, SmartNuclide Biopharma initiated a first-in-human Phase I clinical trial of SNA028, a GPA33-targeted pretargeted radioimmunotherapy (PRIT) for patients with advanced GPA33-positive colorectal cancer.
• In January 2026, Researchers from Kyungpook National University and the Korea Atomic Energy Research Institute published a study demonstrating that dynamic light scattering (DLS) is an effective quality control method for detecting aggregation in ¹??Lu-DOTA-Trastuzumab used in radioimmunotherapy.